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 Abstract: This study characterizes findings on sleep
testing and Human Leukocyte Antigen (HLA) markers in a
group of patients with fibromyalgia (FM) and chronic fatigue
syndrome (CFS). One hundred eighteen patients seen in a
general neurology practice over 5 years meeting standard
clinical criteria for FM or CFS were analyzed retrospectively.
Cases of untreated sleep apnea or restless legs syndrome
were excluded prior to inclusion in this study. Ninety-two
patients had multiple sleep latency testing (MSLT). Seventy-
three (80%) were abnormal by standard criteria. Of 57
females having positive MSLTs, 22 (39%) had one or more
periods of sleep onset rapid eye movement (SOREM), and 5
of 16 (31%) males with positive MSLTs had one or more
SOREM. Highly fragmented sleep, as previously described in
FM, was seen but not analyzed quantitatively. HLA
DQB1*0602 was obtained in 74 patients, and positive in 32
(43%), P < 0.0001 compared with published values in 228
populations. In our patients, who presented with neuromus-
cular fatigue or generalized pain, we found a sleep disorder
characterized by objective hypersomnia. Some patients had
characteristics of narcolepsy. Objective assessment by sleep
studies can assist the diagnostic process, aid future research,
and provide rationale for treatment. 
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INTRODUCTION
The diagnoses of chronic fatigue syndrome (CFS) and
fibromyalgia (FM) are based on clinical criteria. In
1990, The American College of Rheumatology pre-
sented the criteria for FM,1 primarily comprising the
“presence of widespread pain (at least 3 months dura-
tion) and tenderness on 11 of 18 pressure points.” The
Centers for Disease Control and Prevention (CDC)
incorporated these recommendations and added “Fibro-
myalgia is a disorder of unknown etiology characterized
by widespread pain, abnormal pain processing, sleep
disturbance, fatigue and often psychological distress.”2
The CDC defines CFS as a collection of symptoms that
include “chronic, debilitating fatigue” and other vague
complaints that may include pain.2
The descriptions and definitions of these disorders
have substantial overlap, and there is controversy about
the distinction between them. Previously, it has been
difficult to clearly or objectively identify any abnormal-
ity in patients carrying clinical diagnoses of CFS or FM.
Various mechanisms have been proposed, including
viral infections, immunological causes, dysfunction of
the hypothalamic-pituitary-adrenal axis, neurally medi-
ated hypotension, and nutritional deficiencies,3,4 but
despite extensive research, no exact mechanism has been
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proven, nor has treatment aimed at these mechanisms
proven overly successful. The pathophysiology of CFS
and FM is unknown, and these disorders are character-
ized as rather refractory to treatment.
Although the presence of abnormal nocturnal sleep in
FM is recognized, its significance with respect to the
pathophysiology of the disorder is debated. Neither FM
nor CFS has been classified as a disorder of sleep. Com-
plete sleep testing is not part of the routine evaluation
for either, and sleep disturbance is often considered a
secondary phenomenon. The role of excessive daytime
sleepiness has not been investigated systematically in
either condition.
In the course of routine care, a large number of
patients meeting established clinical definitions of CFS,
FM, or both were identified and treated in a neurology
practice. Recurring patterns of sleep disturbance, exces-
sive sleepiness, and fatigue in these patients were noted
frequently, and a large number of sleep studies and HLA
markers were obtained in these patients.
A retrospective analysis of the data was undertaken
because these patients seemed to present fairly stereo-
typical clinical patterns and results on diagnostic testing.
In particular, it was noted that clear hypersomnia was
seen in patients complaining of fatigue. The analysis was
performed to estimate the frequency of daytime hyper-
somnia in these groups of patients. Certain features that
occur in patients with narcolepsy were also noted in
many patients, and this review analyzed some of those
features as well. In view of difficulty distinguishing CFS
and FM, we reviewed our cases to see if the patients
with pain had different sleep findings than the ones with
fatigue only. This review was also undertaken to deter-
mine the consistency of objective sleep-related findings
in these patients and to explore the possibility that sleep
studies could help clinicians in the challenging diagnos-
tic process in these cases.
METHODS
This study comprises a retrospective review of sleep study
and HLA results in 118 patients with CFS and FM that
had all been seen as part of routine care in a general
neurology practice over 5 years, from 2003 to 2008.
Clinical diagnoses of CFS or FM followed standard
published guidelines.1,2,5 In the course of routine care,
sleep studies were recommended to all patients in the
practice clinically identified with excessive sleepiness,
disrupted sleep, or extreme fatigue. These included
patients who presented with generalized pain but who
also had fatigue or sleepiness. While most patients agreed
to the sleep studies, a few patients declined to have them
done. These patients were treated without the results of
the sleep studies if the clinical evidence alone was strong
enough to be deemed sufficient for diagnosis. While the
Epworth Sleepiness Scale (ESS) had been frequently used
to judge the sleepiness in making the recommendations
for the sleep studies, the numerical values were not often
recorded, and so were not available for retrospective
analysis. An elevated ESS was frequently the reason for
recommending a sleep study during clinical treatment.
This retrospective study was approved by the University
of Michigan Institutional Review Board.
Routine polysomnography (PSG) and multiple sleep
latency testing (MSLT) were performed with standard
methodology.6 If other obvious causes of fatigue, such as
sleep apnea or restless legs syndrome, were found on
PSG, those cases were not included in this series. An
MSLT was graded as positive if the latency to sleep on 4
or 5 consecutive naps averaged less than or equal to 8
minutes. Sleep onset rapid eye movement (SOREM)
during these daytime naps of 20 minutes or less was
noted.
Prior to the sleep study, any recently added or
adjusted medications were withdrawn over several
weeks, as were stimulants. However, medications that
the patients had been taking 6 months or longer (in
many cases, for many years) were not withdrawn, so as
not to create sudden changes in their established chronic
physiological state. Typically, these medications would
have included pain medications including opiates, anti-
depressants, medications for control of migraines, and
other long-standing medications. In patients on antide-
pressants and several pain medications, stimulants, and
medications for other chronic conditions, all having
been taken for many years, withdrawal of all of these
over 2 to 4 weeks would cause very significant changes
in physiology and would make assessment of an equi-
librium state impossible. These patients were being
assessed for problems persisting while on (and despite)
these stable medications, and this condition was consid-
ered their steady state.
HLA testing for HLA DQB1*0602 was obtained in
the majority of cases, at 1 laboratory at a major teaching
hospital. The testing was not predicated on sleep study
results and was ordered independently on clinical
grounds. Thus, these markers were not obtained selec-
tively only in patients with positive sleep studies.
Diagnoses of narcolepsy were eventually established
in many of these patients, after the results of complete
evaluation. The diagnosis of narcolepsy followed stan-
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dard clinical practice, which involves the assessment of
multiple criteria to determine the diagnosis. No single
criterion by itself is diagnostic nor exclusive. Criteria
including excessive daytime sleepiness, sleep attacks,
sleep paralysis, and hypnagogic or hypnopompic hallu-
cinations, cataplexy, disrupted nocturnal sleep, abnor-
mal MSLT, and presence and number of SOREM were
all considered.7 The preponderance of evidence, with
emphasis on cardinal features, was used to make the
diagnosis, consistent with good clinical practice.
However, this does not mean every case had exactly the
same exact set of features. The HLA marker itself was
never used to make a diagnosis of narcolepsy. In some
cases where other strongly suggestive pieces of evidence
were present, it was considered as a possible supporting
evidence.
In considering the multiple criteria for narcolepsy, in
the presence of sufficient other pieces of evidence, a single
SOREM was considered supportive of the diagnosis of
narcolepsy. Thus, in retrospectively reviewing these
cases, we counted the cases with one or more SOREM,
when it had also been determined there were other
multiple, adequate combined features of narcolepsy.
RESULTS
A total of 118 charts were identified for retrospective
review. Patients had been treated over the course of
approximately 5 years, from 2003 to 2008. Only a
minority of cases were originally referred for a diagnosis
of CFS (3/118, 2%) or FM (33/118, 28%). Cases were
referred for typical diagnoses that would be seen in a
neurology practice, such as low-back pain, migraine, or
suspected epilepsy. Because of complaints of weakness or
myalgia, many of the cases were referred for consider-
ation of neuromuscular disorders, such as myopathies or
neuromuscular junction disease, or consideration of mul-
tiple sclerosis. None of the cases were originally referred
for a primary sleep disorder. Most of the patients had
been seen previously by rheumatologists or psychiatrists,
as is typical in this group of patients. In many of the cases,
symptoms of CFS or FM were discovered during review
of systems while a patient was being treated for an
unrelated disorder such as migraine or epilepsy, while in
some cases, a diagnosis of CFS or FM had been previ-
ously suggested by another physician but was not the
reason for the neurological consultation.
Twenty-five of the patients were male (21%) and 93
were female (79%), in keeping with the accepted female
preponderance of CFS and FM. The mean age was
53 1 12. These demographics are very similar to pub-
lished demographics of these disorders. Of the 118
patients, 117 (99%) had long-standing fatigue consis-
tent with CFS, and 82 (69%) had generalized pains and
muscle aches in a pattern consistent with FM. Of the 25
male patients, 14 had pain (56%), and of the 92 female
patients, 68 had pain (74%). Thus, while there are more
female than male patients, once the disorder is present,
the clinical characteristics appear fairly similar in males
and females, with males having somewhat less tendency
to pain. The pain was most typically described as “all
over,” as considered characteristic of FM, and as con-
sidered diagnostic of the disorder by standard criteria.
Persisting chronic pain “all over” has been found to be
a strong clinical feature of FM.1 The fatigue was chronic
and long standing, and without other cause, meeting
standard criteria for CFS.2
Any patients having another cause of excessive sleepi-
ness discovered on PSG, such as obstructive sleep apnea
or restless legs syndrome, were excluded from this study,
unless it could be shown on PSG that the condition had
been successfully, completely corrected. Thus, none of
these 118 patients had untreated sleep apnea or restless
legs syndrome.
Of the 118 patients, 92 patients underwent MSLT
(Table 1). Of these 92, 73 (80%) had a positive study by
standard criteria, with a mean sleep onset of less than or
equal to 8 minutes. Among 74 females who had MSLTs,
57 (77%) were positive, whereas among 18 males
having MSLTs, 16 (89%) were positive. Of the 82
patients with generalized pain, 61 had MSLT. Of those
61, 45 had positive MSLTs (74%), while the remaining
16 had negative results. Thus, the majority of patients
with a symptom of generalized body pain who had
Table 1. MSLT Results Obtained in 92 of 118 Patients
who had MSLT Testing. Positive Results Comprise
Average Sleep Latency less than or equal to 8 minutes.
Other Causes of Excessive Sleepiness, including OSA
and RLS, had been Excluded Clinically and by PSG in all
Patients. All Patients had Varying Degrees of Fatigue.
The Group with Pain was Most Consistent with the
Clinical Syndrome of Fibromyalgia. The Remainder had
Little or No Pain, More Consistent with Chronic Fatigue
Syndrome
MSLT Total Positive (%)
Total 92 73 (80)
Male 18 16 (89)
Female 74 57 (77)
Pain 61 45 (74)
MSLT, multiple sleep latency testing; OSA, obstructive sleep apnea; PSG,
polysomnography; RLS, restless legs syndrome.
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MSLT done had significant objective abnormal results
indicating excessive sleepiness. Notably, the values for
patients with pain (74% positive) are similar to the
results for those with fatigue. Objective hypersomnia is
a recurring finding in our patients.
Of the 57 females with positive MSLTs, 22 (39%)
had one or more periods of SOREM, and among the 16
males with positive MSLTs, 5 (31%) had SOREM
(Table 2). Of the patients with negative MSLTs, 6 female
patients had one or more SOREM. Thus, altogether, of
the 92 patients having MSLTs, 33 (36%) had at least 1
period of SOREM. Thus, given the appropriate clinical
symptoms being presented, nearly 40% of patients were
having at least 1 SOREM period, and this was used as a
supportive feature toward the diagnosis of narcolepsy in
the overall context. Other supportive criteria of definite
narcolepsy, such as sleep attacks, cataplexy, sleep
paralysis, or an HLA marker, were also present in these
patients, but an analysis of these criteria separately and
together was not performed.
Subgroup analysis was performed, including, for
example, those with pain and SOREM, or “with pain
and SOREM and positive HLA markers,” however,
many of the subgroups in the analysis became too small
for meaningful results. Data on the individual features
of the clinical characteristics to make the diagnosis, such
as sleep paralysis, nocturnal hallucinations, or cata-
plexy, had not been recorded separately in every case.
The aggregate was often referred to broadly in the clini-
cal diagnosis. Therefore, further subgroup analysis was
not pursued.
Patients used various terms to describe their fatigue.
The numbers of patients using each descriptor were
not recorded quantitatively or consistently in every
chart. Terms used by patients included sleepiness, a
desire to sleep, a desire to sleep but inability to fall
asleep, muscular fatigue, fatigue worsened by physical
exertion or exercise, unrefreshing sleep, light and fitful
sleep, myalgias, unexplained falling episodes without
loss of consciousness, difficulty getting started for the
day or performing routine chores, or difficulty “getting
off the couch.” Initially, it was thought that these
terms would have predictive value, and, as typical in a
clinical neurology practice, great emphasis was placed
on the accurate description of the symptoms. Ulti-
mately, none of the clinical terms served to differenti-
ate or predict sleep study results, nor eventual response
to treatment. Interestingly, they did not predict neuro-
muscular vs. sleep findings, as originally expected. The
data had not been recorded in a quantitative manner
that allowed numerical analysis in this retrospective
review.
A total of 74 patients out of the 118 were tested for
the HLA DQB1*0602 marker (Table 3). Selection for
testing was not based on sleep study results, and gener-
ally, the tests were ordered in parallel on clinical
grounds. Twenty-six of 59 females tested (44%), and 6
of 15 males (40%), were positive. Altogether, 32 of 74
(43%) were found to be positive.
In this retrospective study, formal grading of the noc-
turnal sleep pattern had not been employed during treat-
ment, beyond routine standard measures. The initial
intent of the nocturnal PSG, performed the night before
the MSLT, was to exclude other causes of fatigue, and in
fact, if such were found, those patients were not
included in the study. However, one author (A.R.S.) did
qualitatively assess all PSGs, and all of them showed
inability to achieve deep stage III/IV sleep, inability to
sustain sleep, or most typically, a highly fragmented
pattern of the nocturnal sleep stages. This pattern has
been described in FM by other authors8 and was not
reanalyzed for this study.
DISCUSSION
Disrupted nocturnal sleep has been reported and recog-
nized in patients with FM. The pathophysiological sig-
Table 2. Presence of SOREM. The First Column
Identifies Patients who had Positive MSLTs (See
Table 1). The Second Column Identifies those who had
Positive MSLTs who also had One or more SOREM
during Daytime Naps. The Third Column Identifies
those who had one or more SOREM but who had a
Normal MSLT (were not among the Group in Column 1).
Because of the Small Numbers, a Percentage was not
Calculated for this Group. A more Detailed Discussion is








Male 16 5 (31) 0
Female 57 22 (39) 6
MSLT, multiple sleep latency testing; SOREM, sleep onset REM.
Table 3. Presence of HLA DQB1*0602
HLA Tested Positive (%)
Male 15 6 (40)
Female 59 26 (44)
Total 74 32 (43)
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nificance has been debated, but recent treatment studies
aimed at this nocturnal sleep pattern raise the question
whether the sleep disturbance is a primary, rather than a
secondary, component of the disorder. Our data show
that these patients have clear, substantial, objective
daytime hypersomnia in the face of, and simultaneous
with, this disrupted nocturnal sleep pattern. Patients
with sleep deprivation and sleep apnea will not have
inability to sleep at night, and those with idiopathic
hypersomnia are described as having “longer and more
consolidated nocturnal sleep than do other patients with
daytime sleepiness.”9 Deprivation of deep sleep will lead
to a rebound of increased nocturnal deep sleep during
the recovery phase. Our finding supports the theory
that, in these cases, the inability to sleep at night is
primary rather than secondary. Patients with this degree
of hypersomnia should be attempting to recover with
increased sleep at night. Rather, the pattern is closer to
that of patients with narcolepsy, who have poor noctur-
nal sleep in the face of significant daytime hypersomnia,
and in whom the sleep disorder is primary.
There is debate about the distinction of FM and CFS.
Our results in the subgroups with pain and fatigue, and
fatigue alone, were similar. The lack of a difference in
the sleep data suggests the need for prospective studies
to look at underlying sleep in both groups of patients.
Sleep has not been studied in CFS, and treatment of CFS
has been considered distinctly from FM. Our observa-
tion provides a basis for considering treatments aimed at
sleep in both conditions, CFS included. Our preliminary
data suggest that treatment aimed at the sleep disorder
in CFS may be helpful.
We compared our frequency of the HLA
DQB1*0602 marker with published population preva-
lences of the marker. The allele frequency of HLA
DQB1*0602 was noted to be 0.128 (12.8%) in Olm-
stead County Minnesota.10 Mignot et al. have found an
approximate prevalence of 24% in their population.11
This marker varies in different population groups.
Therefore, we took all reported frequencies of HLA
DQB1*0602 in 228 surveyed populations12 and com-
puted the mean value of these reported frequencies. The
mean value was 0.0798 (7.98%). When our data are
compared with this population prevalence using all 228
studies, the z-score is 11.0, and the P value for a prob-
able difference between the groups is P < 0.0001. It is
still high compared with some of the individual, isolated
studies reporting 12% to 25% prevalence. While the
HLA itself is never used to make a diagnosis of narco-
lepsy, our results of 43% positive for this HLA marker
in this population are over 5 times higher than the
average prevalence in the 228 populations. It is substan-
tially higher than the reported prevalence even in
selected populations. While some individual studies
report higher values than others, it is most meaningful
to compare our results statistically with larger groups of
studies rather than the individual, isolated outliers, par-
ticularly only the highest values.
Our data indicate the need for a prospective study of
HLA markers in the patient population comprising CFS
and FM. It also suggests that a subgroup of these
patients may have an immunological basis for their dis-
order, as is thought to be possible in classical narcolepsy
with cataplexy. Some of these patients, initially classified
as FM or CFS, in fact seem to meet the full criteria for
narcolepsy but are presenting to physicians with an
atypical presentation. In some cases, the diagnosis was
not apparent for decades.
All of the patients in this series had a diagnosis
of narcolepsy made on clinical grounds during
treatment, using various combinations of features. In
the retrospective analysis, the data were not reviewed
to establish the number or type of criteria that had
been used to make the diagnosis in each case. As
formal questionnaires, scoring, and formalized lists of
clinical diagnostic features were not recorded, it would
be difficult to retrospectively reestablish the clinical
picture consistently in all these cases for study
purposes.
Our retrospective study cannot establish the preva-
lence of classical narcolepsy accurately in these
patients. This is partly because of the way the clinical
features had been recorded and partly because this is a
retrospective study. The extent to which patients
meeting the criteria for CFS or FM may have classical
narcolepsy should be evaluated in prospective studies.
Our MSLT and HLA marker results suggest that
this will represent a significant subgroup of these
patients.
In addition to providing information on the preva-
lence of classical narcolepsy, a prospective study will
identify and characterize more clearly the group of
hypersomnic patients who does not meet that defini-
tion. Our data suggest a subgroup of patients may
fall into that category. For example, patients without
the HLA DQB1*0602 marker, or patients without
SOREM on MSLT, may be more likely to have normal
cerebrospinal fluid hypocretin, and may have
another form of hypersomnia. Taken together, our
data suggest the different forms of hypersomnia will be
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identified in a large proportion of patients with CFS
and FM.
We studied our patients while continuing medica-
tions they had taken for prolonged periods of time,
often many years. Many medications are said to affect
the sleep cycle. These medications had been started
after the onset of, and in order to treat, existing symp-
toms, including fatigue and pain. In the setting of pro-
longed habituation to these medications, the degree of
hypersomnolence seems striking. In view of the degree
of objective hypersomnia, the suggestive data from the
HLA markers, and the presence of a group of patients
with clinical syndromes meeting the criteria for narco-
lepsy, we believe there is sleep dysfunction that cannot
be explained by chronic, long-standing medications
prescribed after the onset of symptoms.
This study points toward the presence of a frequent
sleep disorder in CFS and FM, but it does not answer the
question of the underlying etiology of the sleep disorder.
There may be multiple pathways leading to the dysregu-
lation of sleep. Our patients included cases who had
developed symptoms following head trauma, recent
viral infections, recent pregnancy and delivery, and
attacks of demyelinating disease, as some examples. In
other cases, the onset was insidious with no apparent
precursor, or in retrospect, had begun in childhood or
teenage years, or was associated with a positive HLA
marker.
The role of viral agents in CFS has been studied for
years. The localization of brainstem and hypothalamic
control of sleep centers has been studied extensively
recently,13 and the lesions in von Economo’s encepha-
litis could lead to sleep disorders such as those seen in
our patients. Thus, a subgroup of our patients may
represent this etiology, which could have a viral onset.
Recently, a retrovirus has been reported in a group of
patients with CFS.14 Neuroanatomic and physiologic
correlates of the fatigue in those patients are not yet
known. Overall, therefore, the anatomic localization of
the lesion may be the unifying common theme in these
cases.
Many patients with these symptoms are classified as
having a psychiatric disorder, no disorder, or have
trouble establishing a diagnosis and treatment plan.
They seek advice from multiple physicians without any
clear answers, and physicians are in a quandary when
trying to assess these patients. Sleep studies should be
added to the assessment of these patients. Objective
findings on sleep studies will help quantify the fatigue,
provide an objective basis for its presence, reassure
patients and physicians, and help guide treatment plans.
While sleep studies cannot serve as a diagnostic test for
CFS and FM by themselves, the presence of objective
quantifiable abnormalities on these tests can assist cli-
nicians by adding to the subjective criteria currently
employed to define these syndromes. Objective tests are
routinely used in this manner in many syndromes. This
is conceptually similar to the consideration of a positive
ANA or rheumatoid factor, which must be combined
with a clinical picture, but aids in the establishment of a
diagnosis.
Recently reported studies, including a double-blind
placebo-controlled study15 and results in our patients,16
have suggested that treatment with sodium oxybate pro-
vides benefit in patients with FM. While the original
rationale for this treatment had been the described noc-
turnal sleep disturbance, our finding of significant
daytime hypersomnia further extends this rationale,
provides a better understanding of the effectiveness of
this medication, and may help guide future treatment
studies.
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